ACE2 and COVID-19: Current evidence showed that COPD subjects have increased pulmonary expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in lung tissues, which may predispose patients to an increased risk of worse outcomes from COVID-19 [2].